2018 AANS Annual Scientific Meeting-633. Traumatic Intracranial Hemorrhage in the Setting of 4-Factor Prothrombin Complex Concentrate

633. Traumatic Intracranial Hemorrhage in the Setting of 4-Factor Prothrombin Complex Concentrate

Video Transcription

Video Summary

In this video, Dr. Harry Muschlin reports on traumatic intracranial hemorrhage in the setting of four-factor PCC (prothrombin complex concentrate). He explains that the coagulation cascade and clotting factors targeted by different anticoagulation medications, such as Warfarin and NOACs. The traditional treatment for hypocoagulable trauma patients is fresh frozen plasma (FFP), but it has limitations. Dr. Muschlin introduces Kcentra, a 4-PCC product approved by the FDA in 2013, which offers faster reversal times and a smaller volume compared to FFP. He discusses the limited literature and small sample sizes that exist on the use of Kcentra for traumatic intracranial hemorrhage. Dr. Muschlin presents the results of a retrospective review conducted at Shock Trauma, which indicates that Kcentra is a safe and effective alternative to FFP for reversing the INR in trauma patients. However, he emphasizes the importance of preventing hemorrhagic progression or recurrence, as these events significantly impact patient outcomes. The video was presented by Dr. Harry Muschlin, a PGY-5 at the University of Maryland School of Medicine, in collaboration with the Shock Trauma Center in Baltimore. No disclosures are reported.

Asset Caption

Harry Mushlin, MD

Keywords

traumatic intracranial hemorrhage

four-factor PCC

coagulation cascade

anticoagulation medications

Kcentra